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University of Pittsburgh School of Medicine, Pittsburgh, PennsylvaniaABSTRACT Cys-loop receptors are molecular targets of general anesthetics, but the knowledge of anesthetic binding to these
proteins remains limited. Here we investigate anesthetic binding to the bacterialGloeobacter violaceus pentameric ligand-gated
ion channel (GLIC), a structural homolog of cys-loop receptors, using an experimental and computational hybrid approach. Tryp-
tophan fluorescence quenching experiments showed halothane and thiopental binding at three tryptophan-associated sites in
the extracellular (EC) domain, transmembrane (TM) domain, and EC-TM interface of GLIC. An additional binding site at the
EC-TM interface was predicted by docking analysis and validated by quenching experiments on the N200W GLIC mutant.
The binding affinities (KD) of 2.35 0.1 mM and 0.105 0.01 mM were derived from the fluorescence quenching data of halo-
thane and thiopental, respectively. Docking these anesthetics to the original GLIC crystal structure and the structures relaxed by
molecular dynamics simulations revealed intrasubunit sites for most halothane binding and intersubunit sites for thiopental
binding. Tryptophans were within reach of both intra- and intersubunit binding sites. Multiple molecular dynamics simulations
on GLIC in the presence of halothane at different sites suggested that anesthetic binding at the EC-TM interface disrupted
the critical interactions for channel gating, altered motion of the TM23 linker, and destabilized the open-channel conformation
that can lead to inhibition of GLIC channel current. The study has not only provided insights into anesthetic binding in GLIC,
but also demonstrated a successful fusion of experiments and computations for understanding anesthetic actions in complex
proteins.INTRODUCTIONMolecular mechanisms of general anesthesia remain
unsolved. Although there is an ample amount of evidence
for anesthetic modulation on functions of various ion chan-
nels in the central nervous system (1), the knowledge
regarding where anesthetic sites of action are located and
how anesthetics alter the functions of these channels is still
limited. Cys-loop receptors, a superfamily of ligand-gated
ion channels (LGICs), have been identified as potential
anesthetic targets (1,2). Members of the LGIC family
include glycine and GABA receptors with anion-selective
channels and serotonin 5HT3 receptors and nicotinic acetyl-
choline receptors (nAChRs) with cation-selective channels.
The receptors share considerable structural similarity. Each
of them is assembled by five subunits, forming a homo- or
heteropentameric ion channel, and each subunit consists
of an extracellular (EC) domain, four transmembrane
segments (TM1–TM4), and an intracellular domain.
Binding of agonists to the EC domain activates the channel
and produces ion current. The activities of LGICs could be
altered by volatile and intravenous anesthetics. It is believed
that anesthetics modulate the function of LGICs through
direct binding to these receptors (1,2). Experimental proof
of direct anesthetic binding to cys-loop receptors, however,
has been presented only in a few examples (3–5). More
investigations with atomic resolution are required forSubmitted January 21, 2010, and accepted for publication July 15, 2010.
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0006-3495/10/09/1801/9 $2.00a comprehensive understanding of interactions between
anesthetics and cys-loop receptors.
Gloeobacter violaceus pentameric ligand-gated ion
channel (GLIC) is a bacterial homolog of open-channel
nAChRs. Its x-ray crystal structures have been solved with
resolutions of 2.9 A˚ (6) and 3.1 A˚ (7). A recent electrophys-
iology study validated the relevance of GLIC to anesthetic
action (8). Similar to the findings in nAChRs, the channel
current of GLIC could be inhibited by inhaled and intrave-
nous general anesthetics. The low Hill number (0.3) impli-
cated multiple binding sites for some anesthetics, but did
not offer clues as to where the binding sites are and why
binding induces channel inhibition. Collectively, the homol-
ogous nature of GLIC to nAChRs and the preceding exper-
imental findings on GLIC provide several advantages for
mapping anesthetic interaction sites in GLIC. The high-
resolution structure of GLIC allows us to identify anesthetic
binding sites with less ambiguity. The established knowl-
edge of anesthetic inhibition on GLIC channel function
defines the biological relevance of GLIC for exploring the
molecular basis of anesthetic action. The availability of
a relatively large quantity of GLIC through protein expres-
sion makes the investigation of anesthetic effects on struc-
ture and dynamics of GLIC more feasible.
The anesthetic binding sites have been exploited via
various biophysical methods. NMR can sensitively detect
the anesthetic binding sites in proteinswith atomic resolution
(9–15). In addition, NMR can also probe the structural and
dynamical changes of proteins upon anesthetic binding
(9–11,14). However, some technical challenges need to bedoi: 10.1016/j.bpj.2010.07.023
FIGURE 1 Three tryptophan-associated sites in the wild-type GLIC:
W47 and W72 in the EC domain (termed as Site-TrpEC), W160 at the
EC-TM interfacial region (termed as Site-TrpINT), and W213 and W217
in the TM domain (termed as Site-Trp).
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thetic binding on integral protein complexes, such as GLIC.
X-ray structures of anesthetic-protein complexes revealed
anesthetic binding sites with atomic resolution, but the
success has been limited, so far, in soluble proteins (16–19).
Photoaffinity labeling identified the binding sites for halo-
thane, [3H]azietomidate, and TDBzl-etomidate in nAChR
(3,4,20) and [3H]azietomidate in the GABAA receptor (21).
The application of this method for mapping binding sites is
often limited due to a small number of anesthetics that are
equipped with photolabeling probes (22). Tryptophan
(TRP) fluorescence of proteins can be quenched effectively
by anesthetic binding near the TRP residues of the proteins
(23–25). Thus, steady-state fluorescence measurements are
effective for mapping anesthetic binding sites and affinities
(23–26). In the case of GLIC, steady-state fluorescence
experiments are particularly suitable to search for anesthetic
sites. Five intrinsic TRPs are located in three sites in the EC
domain, transmembrane (TM) domain, and EC-TM interface
of GLIC (Fig. 1). They can serve as natural probes for iden-
tifying anesthetic binding sites.
In this study, steady-state fluorescence quenching experi-
ments were fused with computational predictions for
exploring binding information of the volatile anesthetic halo-
thane and intravenous anesthetic thiopental inGLIC. Thefluo-
rescence experiments suggested the binding of halothane and
thiopental at four sites, including three intrinsic TRP-associ-
ated sites and one additional site at the EC-TM interface pre-
dicted by computer docking. The docking analysis provided
not only predictions for potential anesthetic binding sites,
but also details of anesthetic binding sites that the experiments
could not reveal. The subsequentmultiplemolecular dynamics
(MD) simulations of halothane binding to those experimen-
tally predicted sites further explored the underlying cause
for inhibition of GLIC channel current. Taken together,
through experimental corroboration of computational predic-
tion, our study offered what to our knowledge are the first
insights into specific interactions between anesthetics and
GLIC that facilitate the understanding of anesthetic modula-
tionon functions ofGLICandhomologous cys-loop receptors.
MATERIALS AND METHODS
GLIC expression and purification
Wild-type GLIC plasmid was generously provided by Professor Raimund
Dutzler’s group of the University of Zu¨rich, Zu¨rich, Switzerland. The
expression and purification of GLIC followed the previously published
protocols (6,7). Briefly, GLIC was expressed in the Escherichia coli,
extracted with n-dodecyl-b-D-maltoside (Anatrace, Affymetrix, Santa
Clara, CA), and purified with the Ni-NTA column (GE Healthcare, Wauke-
sha, WI) before and after HRV3C (GE Healthcare) digestion. The purified
GLIC was stored at 4C in 10 mM potassium phosphate (pH 8.0), 150 mM
NaCl, and 0.025% n-dodecyl-b-D-maltoside. Before the fluorescence
quenching experiments, the sample buffer was exchanged to 10 mM sodium
acetate (pH ~4) to ensure an open-channel conformation of GLIC (6,7). The
final protein concentrations were determined using a DU800 UV/Vis
Spectrometer (Beckman Coulter, Fullerton, CA).Biophysical Journal 99(6) 1801–1809Site-directed mutagenesis
Five tryptophan residues in a wild-type GLIC are situated at three different
sites, as shown in Fig. 1. We generated three mutants to dissect the
anesthetic binding information at each site. Each mutant contained trypto-
phan(s) at only one site; all other tryptophans were mutated to tyrosines.
Thus, the mutant GLICEC has W47 and W72 in the extracellular domain,
GLICINT has only W160 at the interface of extracellular and transmem-
brane domains, and GLIC has W213 and W217 in the transmembrane
domain. N200 was predicted computationally as being involved in anes-
thetic binding. GLICN200W was made with replacing all natural tryptophans
to tyrosines. All site-directed mutagenesis were done using the QuikChange
Multi Site-Directed Mutagenesis Kit (Qiagen, Valencia, CA). The plasmid
DNAs were collected and purified using the QIAGEN miniprep kit, and
confirmed by sequencing. The mutants were expressed and purified using
the same protocol as for wild-type GLIC.Fluorescence quenching experiments
Anesthetic halothane or thiopental binding to GLIC was determined by
steady-state intrinsic tryptophan fluorescence measurements on a Lumines-
cence spectrometer LS50B (PerkinElmer, Waltham, MA). The tryptophan
fluorescence was excited at 295 nm. The emission spectra were recorded
in the ranges of 320–370 nm and 315–450 nm for halothane and thiopental
quenched samples, respectively. The fluorescence peak maximums were
~333–345 nm for the wild-type GLIC and four mutants. The excitation
slit width was kept at 10 nm whereas the emission slit width was adjusted
based on the fluorescence intensity of each sample. The recorded fluores-
cence spectra were the average of three or four scans. For each experiment,
the sample premixed with an anesthetic was titrated to the same sample that
was initially anesthetic free. The mixture was sealed in a quartz cell of
FIGURE 2 Fluorescence quenching of wild-type GLIC (square),
GLICEC (circle), GLICINT (triangle), and GLIC (diamond) by various
concentrations of (A) volatile anesthetic halothane and (B) intravenous
anesthetic thiopental. (Solid lines) Nonlinear fitting of experimental data
to Eq. 2. The experimental error bars (~5%) are omitted for clarity. The
maximum quenching Qmax and anesthetic disassociation constant KD
from fittings are presented in Table 1. The quenching of wild-type GLIC
by potassium bromide (pentagon) was included in panel A as reference.
Anesthetic Binding to GLIC 18034-mm pathlength using a Teflon stopper. To prevent halothane evaporation,
the premixed sample was stored in gas-tight glass vial and the fresh mixture
was used at each halothane concentration. The fluorescence quenching
experiments were also performed on GLIC using potassium bromide to
evaluate quenching by Br due to nonspecific binding or collision. The
quenched fluorescence by anesthetics, Q, was normalized as
Q ¼ 1 F
F0
; (1)
where F0 and F are the fluorescence intensity in the absence and presence of
anesthetics, respectively. The maximum possible quenching (Qmax) at the
infinite anesthetic concentration, the quenched fluorescence (Q) at anes-
thetics concentration ([A]), and the anesthetic binding affinity (KD) at the
selected tryptophan residue follow the relationship (23,27)
F
F0
¼ 1 Q ¼ 1 Qmax½A
KD þ ½A: (2)
Anesthetics docking in GLIC
Anesthetic sites in GLIC were predicted through flexible docking using the
AUTODOCK program (version 3.0.05) (28) on the original crystal structure
of GLIC (Protein DataBank (PDB): 3EAM) and snapshots of GLIC after
MD simulations for 2 ns, 5 ns, and 10 ns. These relaxed GLIC structures
may offer different docking results from the original crystal structure.
Inhaled anesthetic halothane and intravenous anesthetic thiopental were
investigated. Five-hundred independent docking runs were performed using
a Lamarckian genetic algorithm. A grid spacing of 0.375 A˚ and grid size of
256  256  280 were utilized to span the entire protein structures. The
maximum number of energy evaluations was set to 25,000,000. The dock-
ing energy is the average from the energies of the docked anesthetic at
a same site. Docking occupancy represents the docking probability within
500 runs. The molecular surface (Connolly’s surface) and volume of a puta-
tive anesthetics binding pocket were calculated using CASTp (29).
Molecular dynamics simulations
and data analysis
MD simulations were performed on three systems:
1. A control without anesthetics.
2. Three halothane molecules near the TM23 loops in the crystal structure
(termed as 3HAL-near-TM23).
3. Four halothane molecules near TRP residues in the structure experienced
a 5-ns MD simulation (termed as 4HAL-near-TRPs) (see Fig. S1 of the
Supporting Material).
Halothane was chosen over other anesthetics because it has the optimized
parameters required for MD simulations (30). Details on system preparation
and MD simulations are provided in the Supporting Material. Briefly,
deprotonations of acidic residues at pH ¼ 4.6 were chosen randomly
based on the Henderson-Hasselbach equation and the pKa calculations by
Bocquet et al. (6). The x-ray structure of GLIC (PDB: 3EAM) was inte-
grated with a fully hydrated and preequilibrated binary POPE-POPG
(3:1) lipid mixture. Each simulation system was energy-minimized and
followed by an equilibration simulation. MD simulations were performed
using the NAMD2 package (31) with CHARMM27 force field with
CMAP corrections (Ver. 31) (32). All three systems underwent unrestrained
Nose´-Hoover constant pressure (P ¼ 1 bar) and temperature (T ¼ 310 K)
(33,34) (NPT) simulation for >10 ns. An additional system of the mutant
N200W GLIC was set up and equilibrated for 2 ns using similar protocols
as described in the Supporting Material.
VMD (35) with home-developed scripts was used for data analysis and
visualization. Pore-radius profiles were computed using the HOLE program(36). The system stability over the course of simulation was assessed using
the Ca root mean-square deviation (RMSD) with respect to the crystal
structure. The protein dynamics was evaluated from the root-mean-square
fluctuation (RMSF).RESULTS AND DISCUSSION
Fluorescence quenching revealed multiple
anesthetic binding sites in GLIC
Halothane and thiopental demonstrated high binding
capabilities in GLIC. As shown in Fig. 2, both drugs
quenched >80% of the intrinsic tryptophan fluorescence
in a saturable manner. To prove that the observed quenching
by halothane and thiopental resulted not from nonspecific
collision, we performed the fluorescence quenching experi-
ments on the same GLIC sample with KBr. The rationale for
choosing Br is based on the fact that the bromine atom of
halothane and the negative charge of thiopental are consid-
ered as effective elements for quenching tryptophan fluores-
cence. Br is highly soluble in GLIC samples and has
nonspecific collision with GLIC. As expected, the Br colli-
sion did not produce significant fluorescence quenching
(<5%) on GLIC when Br was in the same concentration
range as halothane (Fig. 2 A) or even in a much higher
concentration (data not shown). The saturable quenchingBiophysical Journal 99(6) 1801–1809
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from the insensitive quenching by Br, suggesting that
halothane and thiopental quenching was not due to nonspe-
cific collisions.
The data fitting to Eq. 2 resulted in the dissociation
constant KD of 0.105 0.01 mM and the maximum quench-
ing Qmax of 100 5 2% for thiopental, and KD of 2.3 5
0.1 mM and Qmax of 86 5 1% for halothane. A higher
binding affinity of thiopental than halothane in GLIC is
consistent with their relative binding affinities in homolo-
gous cys-loop receptors and the difference of their clinical
potencies (37,38). The experiments on individual GLIC
mutants confirmed that both halothane and thiopental could
quench all three TRP-associated sites (GLICEC, GLICINT,
and GLIC) up to saturation (Fig. 2). The KD and Qmax
values of halothane and thiopental in GLICWT and the
mutants are summarized in Table 1.
Several notions can be derived from these data.
First, there are multiple anesthetic sites of similar binding
affinities in GLIC. The finding implicates a possibility that
multiple anesthetic sites may also exist in homologous
proteins, such as cys-loop receptors. Indeed, our recent
computational studies identified multiple halothane binding
sites in neural nAChRs (39,40). Multiple residues of
Torpedo californica nAChRs were also found photolabeled
by [3H]azietomidate (3).
Secondly, because the inhaled anesthetic halothane and
the intravenous anesthetic thiopental have quite different
chemical properties and molecular sizes, it is unlikely that
they occupy the same sites in GLIC. The same pattern of
tryptophan quenching may not necessarily indicate the iden-
tical binding sites for halothane and thiopental.
How do those TRP-associated sites differ for halothane
and thiopental?
Do halothane and thiopental have other interaction sites
in GLIC besides the aforementioned three intrinsic
TRP-associated sites?
How can anesthetic binding alter the function of GLIC?
The answers have been explored with anesthetic docking,
additional experiments inspired by docking, and MD simu-
lations.TABLE 1 Results of GLIC fluorescence quenching by
anesthetic halothane and thiopental
GLIC
Halothane Thiopental
Qmax KD (mM) Qmax KD (mM)
GLICWT 0.865 0.01 2.3 5 0.1 1.005 0.02 0.105 0.01
GLICECD 0.905 0.02 1.3 5 0.2 1.005 0.05 0.115 0.02
GLICINT 0.845 0.02 1.7 5 0.2 0.945 0.02 0.0675 0.005
GLICTMD 0.855 0.01 2.5 5 0.1 1.005 0.03 0.135 0.01
GLICN200W 0.955 0.03 3.4 5 0.3 0.975 0.01 0.0675 0.003
Values of apparent maximum quenching (Qmax) and anesthetic disassocia-
tion constant (KD) were derived from fitting the quenching data to Eq. 2 in
the text.
Biophysical Journal 99(6) 1801–1809An additional binding site at the EC-TM interface,
predicted by docking and validated by
fluorescence quenching
Docking thiopental and halothane to the x-ray structure of
GLIC or its relaxed structures after MD simulations identi-
fied the binding sites that were compatible with fluorescence
quenching. In addition, the docking predicted another
major binding site consisting of N200 of TM1 and residues
(E243, P247, and T249) of the TM23 loop in the adjacent
subunit (termed as Site-near-TM23-loop; see Fig. S2). To
verify this docking prediction, we mutated N200 to trypto-
phan and performed fluorescence quenching on GLICN200W.
As shown in Fig. 3, both halothane and thiopental could
quench the fluorescence of GLICN200W with binding
affinities slightly weaker than or equivalent to those in three
intrinsic tryptophan-associated sites. Compared to the
intrinsic tryptophan-associated site in GLICINT, the Site-
near-TM23-loop is closer to the TM domain at the EC-
TM interface (Fig. 4 D). Nevertheless, the importance of
the EC-TM interface for anesthetic binding is validated by
this study.Halothane binding is more sensitive than
thiopental to subtle changes in protein structure
The original crystal structure of GLIC and the structure
snapshots after multiple nanosecond MD simulations
yielded similar major binding sites for thiopental docking.FIGURE 3 Fluorescence quenching of GLICN200W, a mutant of the anes-
thetic binding site predicted by computer docking, by (A) volatile anesthetic
halothane and (B) intravenous anesthetics thiopental. The solid lines re-
sulted from nonlinear fitting of the experimental data using Eq. 2. The error
bars are the standard deviations of three experiments. The fitting results are
included in Table 1.
FIGURE 4 Halothane molecules (van der Waals format) at putative
binding sites near TRP residues (licorice format) of GLIC or N200W of
the mutant, suggested by halothane docking on the MD-relaxed protein
structures. (A) Near W47 and W72 in the EC domains of GLIC; (B) near
W160 at the EC-TM regions; (C) near W213 andW217 in the TM domains;
and (D) near N200Wat the EC-TM regions of the mutant. Note that most of
halothane molecules are bound to the pocket within a subunit. Bromide or
chloride atom of halothane interacts directly with the indole ring of TRP at
most sites.
FIGURE 5 Predicted binding for intravenous anesthetic thiopental near
W160 at the pocket between two subunits colored in lime and orange.
Docking was performed on a snapshot of GLIC after a 5-ns MD simulation
in a fully hydrated POPG-POPE mixture. Only the docking with the lowest
energy was shown. Thiopental is highlighted with mesh surfaces. Sulfur
atom of thiopental is shown in a large yellow sphere. Oxygen, nitrogen,
carbon, and hydrogen of anesthetics are shown in red, blue, tan, and white,
respectively. Sulfur atom of thiopental interacts directly with the indole ring
of TRP.
Anesthetic Binding to GLIC 1805Three intrinsic tryptophan-associated sites and the mutation
site of N200W were identified for thiopental binding. More-
over, the docking also correctly predicted the site near
W160 (termed Site-TrpINT) for the highest affinity of thio-
pental binding. Detailed docking results are summarized
in Table S1.
In contrast, halothane docking seemed much more sensi-
tive to subtle changes in GLIC structure. In the original
crystal structure, the docking predicted the Site-near-
TM23-loop and the site near D86 and D88 in the EC domain
(termed as Site-near-EC-D86), but could not allocate
the sites with intrinsic tryptophans. When halothane was
docked to a relaxed structure, even a snapshot of GLIC after
2-ns simulation, those sites identified by our quenching
experiments became apparent. Fig. 4 depicts representative
halothane docking at these sites. The bromine or chlorine
atom of halothane is oriented toward the indole ring of
TRP in most sites that could yield effective fluorescence
quenching.
The sensitivity of halothane docking to various subtle
changes in GLIC structure may result from the intrinsically
low binding affinity of halothane. The fact that both original
x-ray and MD-relaxed structures of GLIC offered some, but
not all, experimentally validated binding sites in halothane
docking indicates the existence of the structural ensemble,in which GLIC structural variation is subtle enough to
keep thiopental binding but sufficient to affect halothane
binding. Alignment of the original x-ray structure and the
structure after 5-ns MD simulations showed a small struc-
tural difference (Fig. S3). Relative to the original crystal
structure, Ca RMSDs of a whole and an individual subunit
structure of GLIC after 5-ns MD simulation were 2.0 A˚ and
1.2 A˚, respectively. The MD relaxed structures showed
comparatively looser intersubunit contacts and slightly
expanded intrasubunits. Why did large size thiopental
remain at the same binding sites whereas smaller halothane
relocated to new sites when the GLIC structure changed
from a rigid to a more relaxed form? It turned out that the
binding pockets for halothane and thiopental were not
entirely overlapped, even though both could quench the
same tryptophan residues.Different binding preference to intra- and
intersubunit pockets
As shown in Fig. 4, halothane occupied predominately intra-
subunit pockets and presumably quenched tryptophan fluo-
rescence mainly through interaction within the subunit. In
contrast, thiopental seemed to interact with tryptophans
through the intersubunit pocket. Fig. 5 displays such an
example, where the Site-TrpINT for thiopental was formed
by residues of the F loop (or b8-b9) and b1-b2 loop from
one subunit and K248 in the TM23 loop from the otherBiophysical Journal 99(6) 1801–1809
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nearby indole ring of TRP. Although both halothane and
thiopental were within reach of the highly conserved resi-
dues D122, D32, R192, and W160 in the GLIC (Fig. 4 B
and Fig. 5), and W160 could be quenched by them in the
fluorescence experiments, their binding pockets were not
exactly overlapped. Smaller size halothane preferred the
intrasubunit pocket for optimizing its interaction with
surrounding resides. The intrasubunit pocket near W160 in
the original crystal structure was too small (~60 A˚3) for
halothane, but the pocket size expanded to a volume of
130~300 A˚3 through MD simulations and became large
enough for halothane binding (Fig. S3). Thiopental is larger
than halothane and could fit only into the intersubunit
pocket. The larger surface area of thiopental made its inter-
action with protein more robust so that a 10% pocket
volume change in the MD-relaxed structure did not change
the docking results.FIGURE 6 Putative binding of intravenous anesthetic thiopental inside
the GLIC channel, predicted by docking on the MD relaxed GLIC structure.
For clarity, only four TM2 subunits are shown. Residues S226, I233, and
I240 are plotted in licorice format. Sulfur atom of thiopental is shown in
a large sphere. Oxygen, nitrogen, carbon, and hydrogen of anesthitcs are
colored differently. The docking energy of thiopental is 5.2 5 0.3
Kcal/mol and the docking occupancy is 4%.Possibilities for anesthetics to act as channel
blockers
In addition to the aforementioned major sites with high
occupancy and affinity, docking predicted possible binding
inside the channel for intravenous anesthetic thiopental,
but not for halothane. Thiopental could dock to a region
between S226 and I240 inside the channel lumen with
comparatively weaker binding affinity than the major
binding sites (see Fig. 6). It is interesting to note that
in the crystal structure (PDB: 3EAM), several detergent
molecules are found inside the channel lumen at a region
corresponding to the intravenous anesthetic docking sites
revealed here. Although the validity of these docking
predictions needs to be confirmed, these docking predictions
are certainly valuable for designing future experiments.Halothane binding induced structural
and dynamical consequences on GLIC
To determine how anesthetic binding affects GLIC
dynamics that may impact GLIC function, we performed
multiple MD simulations on several GLIC systems in the
absence and presence of halothane (see Fig. S1). In all
systems, GLIC pentameric structures remained stable and
the maximum Ca RMSD from the initial crystal structure
was only 2.4 5 0.3 A˚ after 10-ns MD simulations. The
backbone pore radius profiles of GLIC in all systems were
similar to the one in the original crystal structure (see
Fig. S4), indicating that halothane binding did not cause
significant structural changes.
Over the course of>10-ns simulations, halothane resided
stably in majority binding sites. The exceptions were found
in the 4HAL-near-TRPs system, where two halothane mole-
cules in the Site-TrpEC and Site-Trp moved away from
their initial docked sites within a 1-ns MD simulation.Biophysical Journal 99(6) 1801–1809This seemingly short residing time is probably long enough
for fluorescence quenching, considering the picoseconds to
nanoseconds lifetime of tryptophan fluorescence in protein
(41,42).
The MD simulations demonstrated that halothane binding
could affect the protein dynamics, especially at the EC/TM
interface. Halothane binding to the Site-near-TM23-loop
(see Fig. S1 A) decreased the RMSF of the TM23-loop
and some regions in EC domains but significantly increased
the RMSF of the b6-b7 loop (corresponding to the cys-loop
in the nAChR), as demonstrated in Fig. 7. Both the TM23-
loop and the cys-loop were suggested to play an important
role in the channel gating for cys-loop receptors (43–45).
Changes in their flexibility by halothane may impact on
the function of GLIC. Moreover, halothane was found to
disrupt interactions between critical residues of GLIC.
In the 4HAL-near-TRPs system, halothane near W160 per-
turbed the salt bridges between D32 and R192 (see Fig. 8),
increased the probability of breaking D32-R192 salt bridges
by>40%, and increased residue fluctuation near the binding
sites by >20%. Homologous salt-bridges in nAChR, i.e.,
a1-E45 and a1-R209 nAChR, were suggested to be partic-
ularly important for channel gating and functions (44).
Removing these salt-bridges by mutations dramatically
FIGURE 7 (A) Comparison of the subunit root-
mean-squared-fluctuation (RMSF) of GLIC in the
absence (black) and presence (red) of halothane
near N200 over the last 1-ns simulation. (B) The
ratio of RMSFs in the presence and absence of
halothane is color-coded onto a subunit structure
of GLIC. The regions having values significantly
smaller (i.e., reducing RMSF) or greater (i.e.,
increasing RMSF) than one are colored in blue or
red, respectively. The regions in white color had
no significant change in RMSF.
Anesthetic Binding to GLIC 1807reduced the open channel stability in the ligand-gated ion
channels (45–47). Thus, halothane binding near W160
may inhibit the channel current through decreasing open
channel stability. Because thiopental binding to the W160
site was also confirmed, it is very likely that thiopental
inhibits GLIC function via a similar mechanism.CONCLUSIONS
Several important conclusions have emerged in this experi-
mental and computational hybrid study.
First, multiple anesthetic binding sites of similar bind-
ing affinities exist in open-channel GLIC. Previous
investigations of nAChRs also found multiple anesthetic
interaction sites in both open- and closed-channel structures
(3,4,26,40,48). It is possible that this is a common property
shared by all cys-loop receptors.
Secondly, smaller size volatile anesthetics, such as halo-
thane, prefer the binding sites within a subunit, whereas
larger size intravenous anesthetics, such as thiopental, prefer
the binding sites between two subunits. Sometimes the intra-FIGURE 8 (A) Salt bridge between D32 and R192 in the control system of G
Halothane interacts with R192, and (C) halothane interacts with D32. Halothane
sented in licorice format.and intersubunit binding pockets could partially overlap, as
evidenced in our finding that tryptophans in GLIC could be
quenched by both halothane and thiopental.
Thirdly, anesthetic binding at the EC-TM interface of
GLIC destabilized the open-channel conformation, which
could be the major cause for inhibition of the channel
current (8).
Finally, it seems premature to conclude that intravenous
anesthetics can block the GLIC channel solely based on
the docking results. However, such a prediction is worth
testing in future experiments, considering that indeed there
are several detergent molecules inside the GLIC channel in
one of the original crystal structures (6).SUPPORTING MATERIAL
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